Henry Khederian
·
September 22, 2025
Benzinga
Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.
read more
October 7, 2025
September 5, 2025
August 18, 2025
Bloomberg
September 4, 2025
Barchart
August 6, 2025